Cargando…
Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths in the US. Cancer-associated cachexia is present in up to 80% of PDAC patients and is associated with aggressive disease and poor prognosis. In the present studies we evaluated an anti-cancer natural product...
Autores principales: | Shukla, Surendra K., Dasgupta, Aneesha, Mehla, Kamiya, Gunda, Venugopal, Vernucci, Enza, Souchek, Joshua, Goode, Gennifer, King, Ryan, Mishra, Anusha, Rai, Ibha, Nagarajan, Sangeetha, Chaika, Nina V., Yu, Fang, Singh, Pankaj K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747396/ https://www.ncbi.nlm.nih.gov/pubmed/26510913 |
Ejemplares similares
-
Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia
por: Shukla, Surendra K, et al.
Publicado: (2014) -
Correction: Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia
por: Shukla, Surendra K, et al.
Publicado: (2014) -
MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer
por: Goode, Gennifer, et al.
Publicado: (2017) -
Correction: MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer
por: Goode, Gennifer, et al.
Publicado: (2017) -
Metabolic Alterations in Pancreatic Cancer Progression
por: Vernucci, Enza, et al.
Publicado: (2019)